In silico exploration of PD-L1 binding compounds: Structure-based virtual screening, molecular docking, and MD...

Area of Science:

• Immunology
• Computational Chemistry
• Pharmacology

Background:

• Programmed death-ligand 1 (PD-L1) is a transmembrane protein crucial for immune system regulation.
• Overexpression of PD-L1 in cancers enables tumor cells to evade immune detection.
• Inhibiting PD-L1 is a promising therapeutic strategy in cancer immunology.

Purpose of the Study:

• To identify novel small molecules for PD-L1 inhibition using structure-based virtual screening.
• To evaluate the binding affinity and stability of potential drug candidates.
• To assess the drug-likeness of identified compounds through ADMET analysis.

Main Methods:

• Structure-based virtual screening of drug libraries against PD-L1.
• Molecular docking to determine optimal binding poses and affinities.
• Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) analysis.
• 200 ns molecular dynamics simulations for top compounds.

Main Results:

• Ten compounds exhibited high binding affinities to PD-L1, ranging from -10.734 to -10.398 kcal/mol.
• Selected compounds demonstrated favorable ADMET properties.
• Molecular dynamics simulations confirmed binding stability without significant conformational changes to PD-L1.

Conclusions:

• The identified compounds are potential lead candidates for PD-L1 inhibition.
• These findings support further in vitro investigation for developing novel cancer immunotherapies.
• The study highlights the utility of computational methods in drug discovery for PD-L1 targeted therapies.